Corvus Pharmaceuticals, Inc
863 Mitten Road, Suite 102
Burlingame
CA
94010
United States
90 articles about Corvus Pharmaceuticals, Inc
-
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
3/25/2021
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2020.
-
Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
3/5/2021
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company’s management will participate in two upcoming investor conferences
-
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock
2/17/2021
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the completion of its previously announced underwritten public offering of 9,783,660 shares of its common stock, which includes 1,212,231 shares of common stock pursuant to the underwriters’ partial exercise of their option to purchase additional shares of common stock, at a price to the public of $3.50 per share. All shares in the offeri
-
Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2/12/2021
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price to the public of $3.50 per share, for gross proceeds of $30.0 million before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by Corvus
-
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock - Feb 11, 2021
2/11/2021
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has commenced an underwritten public offering of shares of its common stock.
-
Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19
2/4/2021
Novel immunotherapy approach designed to stimulate immune response by activating B cells to enhance polyclonal antibody production and potentially reduce hospitalization and progression to respiratory failure Randomized, double-blind, placebo-controlled study expected to enroll ~1,000 patients across global sites with results expected in Q4 2021 Company to host conference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT
-
Corvus Announces Participation in Upcoming Investor Conferences
9/8/2020
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the following investor conferences:
-
Corvus Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
8/4/2020
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference.
-
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
7/30/2020
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and announced financial results for the second quarter ended June 30, 2020.
-
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2020 Financial Results on July 30, 2020Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
7/23/2020
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on July 30, 2020 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2020 financial results. The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) and using the conference ID 10010533. T
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.
-
Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19
7/7/2020
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19.
-
Corvus Pharmaceuticals Presents Updated Clinical Data Supporting and Refining the Adenosine Gene Signature’s Ability to Identify Patients Likely to Respond to Treatment with Ciforadenant
5/29/2020
Elucidation of CD68 as a Downstream Target of Adenosine Refines Adenosine Gene Signature into a Practical Pathology Test Provides Opportunity to Further Enrich Patient Selection for Responders
-
Corvus Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference
5/27/2020
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, today announced that the company will present at the Jefferies 2020 Virtual Healthcare Conference. The presentation is scheduled for Tuesday, June 2, 2020 from 2:00 – 2:25 pm Eastern Time. A webc
-
Corvus Pharmaceuticals to Present Data on Refinement of the Adenosine Gene Signature and Ciforadenant in Renal Cell Cancer at the ASCO20 Virtual Scientific Program
5/13/2020
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, today announced that updated data reporting refinements of the Adenosine Gene Signature
-
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results
4/30/2020
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, provided a business update and announced financial results for the first quarter ended March 31, 2020.
-
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2020 Financial Results on April 30, 2020Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
4/22/2020
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, today announced that the Company will host a conference call and webcast on April 30, 2020 at 4:30 pm ET (1:30 pm PT) to provide a business update and report first quarter 2020 financial results.
-
For nearly 30 years, Richard Miller has been at the forefront of developing treatments for lymphomas, most notably the multi-billion dollar breakthroughs Rituxan and Imbruvica. In recognition of his decades of work, Miller was awarded with the 2020 Drug Hunter Award.
-
Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting
12/7/2019
Selective ITK inhibitor was well tolerated with demonstration of specific target occupancy
-
Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/8/2019
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced updated results from its Phase 1/1b trial of CPI-006, the Company’s anti-CD73 antibody.